Catalent Inc (CTLT) Stock Rating Reaffirmed by J P Morgan Chase & Co
Catalent Inc (NASDAQ:CTLT)‘s stock had its “buy” rating restated by investment analysts at J P Morgan Chase & Co in a research note issued to investors on Tuesday. They currently have a $40.00 price target on the stock. J P Morgan Chase & Co’s price objective would suggest a potential upside of 1.60% from the stock’s previous close.
Several other equities analysts have also recently weighed in on CTLT. Piper Jaffray Companies reiterated a “buy” rating and set a $45.00 price objective on shares of Catalent in a report on Tuesday. Zacks Investment Research raised Catalent from a “hold” rating to a “buy” rating and set a $39.00 target price on the stock in a research report on Tuesday, August 22nd. BidaskClub raised Catalent from a “sell” rating to a “hold” rating in a research report on Wednesday, August 16th. Bank of America Corporation reaffirmed a “buy” rating and set a $38.00 price target (up previously from $37.00) on shares of Catalent in a research report on Friday, July 21st. Finally, William Blair raised Catalent from a “market perform” rating to an “outperform” rating in a research report on Monday, May 15th. Three analysts have rated the stock with a hold rating and six have issued a buy rating to the stock. The stock presently has a consensus rating of “Buy” and an average price target of $35.88.
Shares of Catalent (CTLT) opened at 39.37 on Tuesday. The stock has a 50 day moving average of $35.14 and a 200 day moving average of $32.37. Catalent has a 1-year low of $21.83 and a 1-year high of $40.44. The firm has a market cap of $4.93 billion and a PE ratio of 45.25.
Catalent (NASDAQ:CTLT) last announced its quarterly earnings data on Monday, August 28th. The company reported $0.65 EPS for the quarter, topping the Zacks’ consensus estimate of $0.57 by $0.08. Catalent had a return on equity of 16.95% and a net margin of 4.88%. The firm had revenue of $616.90 million during the quarter, compared to analyst estimates of $547.48 million. During the same period last year, the company earned $0.52 earnings per share. The company’s revenue was up 15.9% on a year-over-year basis. Equities research analysts anticipate that Catalent will post $1.60 earnings per share for the current fiscal year.
In related news, SVP Christine Dolan sold 745 shares of the company’s stock in a transaction dated Tuesday, August 1st. The stock was sold at an average price of $34.85, for a total transaction of $25,963.25. The sale was disclosed in a document filed with the SEC, which is accessible through this hyperlink.
Hedge funds and other institutional investors have recently made changes to their positions in the company. Acrospire Investment Management LLC raised its position in Catalent by 72.2% in the second quarter. Acrospire Investment Management LLC now owns 3,100 shares of the company’s stock worth $109,000 after buying an additional 1,300 shares in the last quarter. Quantbot Technologies LP increased its stake in shares of Catalent by 110.7% in the second quarter. Quantbot Technologies LP now owns 3,434 shares of the company’s stock worth $120,000 after buying an additional 1,804 shares during the last quarter. Flinton Capital Management LLC increased its stake in shares of Catalent by 17.7% in the first quarter. Flinton Capital Management LLC now owns 3,616 shares of the company’s stock worth $102,000 after buying an additional 544 shares during the last quarter. Meadow Creek Investment Management LLC increased its stake in shares of Catalent by 17.7% in the first quarter. Meadow Creek Investment Management LLC now owns 4,972 shares of the company’s stock worth $141,000 after buying an additional 748 shares during the last quarter. Finally, Zurcher Kantonalbank Zurich Cantonalbank increased its stake in shares of Catalent by 12.5% in the second quarter. Zurcher Kantonalbank Zurich Cantonalbank now owns 5,043 shares of the company’s stock worth $177,000 after buying an additional 559 shares during the last quarter.
Catalent Company Profile
Catalent, Inc provides delivery technologies and development solutions for drugs, biologics, and consumer and animal health products. Its segments include Softgel Technologies, Drug Delivery Solutions and Clinical Supply Services. The Softgel Technologies segment is engaged in the formulation, development and manufacturing of prescription and consumer health soft capsules or softgels.
Receive News & Stock Ratings for Catalent Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Catalent Inc and related stocks with our FREE daily email newsletter.